ARTICLE | Clinical News
CV Therapeutics completes CARISA Phase III
August 8, 2001 7:00 AM UTC
CVTX completed enrollment of more than 700 chronic angina patients in a 12-week, double-blind, placebo-controlled international Phase III trial of ranolazine. The CARISA (combination assessment of ran...